Breaking News

Low-dose methotrexate for moderate-severe adult atopic dermatitis

Low-dose methotrexate for moderate-severe adult atopic dermatitis


A retrospective study assessed the efficacy and safety of oral or intramuscular methotrexate, 10-25 mg/week for 8-12 weeks in 20 adult patients with moderate-severe atopic dermatitis (AD) unresponsive to previous treatments. Patients also received 5 mg folic acid/week. Response was assessed by the SCORing Atopic Dermatis index (SCORAD), Dermatology Life Quality Index (DLQI) and a global assessment of the SCORAD and DLQI. There were 16 responders and four nonresponders. Both mean SCORAD and DLQI scores fell significantly after treatment, by 44.3 and 43.5%, respectively. Treatment was more effective in those with adult onset as opposed to childhood onset AD. Methotrexate was well tolerated, although three patients required brief discontinuation of treatment (Lyakhovitsky, ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list